-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
introduction
introduction On November 18, 2021, the Center for Drug Evaluation undertook the listing application of Boehringer Ingelheim's Class 1 biological product Spesolimab injection (Spesolimab)
.
(Source: CDE official website)
Spesolimab Spesolimab is an IL-36R (interleukin-36 receptor) monoclonal antibody that can block the effect of IL-36R receptor.
It is the first treatment of its kind under development
.
Studies have confirmed that it can significantly improve the symptoms of Generalized Pustular Psoriasis (GPP)
Spesolimab IL-36R Boehringer Ingelheim
Boehringer Ingelheim has substantially increased its R&D investment since 2020, aiming to develop innovative drugs and therapies for diseases that cannot be effectively treated
.
In 2020, Boehringer Ingelheim's total R&D expenditure will reach 3.
7 billion euros
At present, Boehringer Ingelheim has a product pipeline consisting of more than 40 preclinical drugs and more than 15 clinical stage drugs covering cardiovascular diseases, tumors, respiratory diseases, immunity, central nervous system diseases, retinal diseases and other therapeutic fields
.
(Pipeline source: Boehringer Ingelheim official website)
Reference source:
Reference source: Reference source:[1] CDE official website
[1] CDE official website[2] boehringer-ingelheim.
com[2] boehringer-ingelheim.
com